Q3 EPS Forecast for Sarepta Therapeutics Lifted by Analyst

Key Points

• Leerink Partners has revised its Q3 2026 earnings per share estimate for Sarepta Therapeutics upward to $2.20, reflecting increased optimism about the company's financial performance.
• The company's most recent quarterly earnings report showed a significant increase in revenue, which rose by 68.4% year-over-year, leading to an earnings per share of $2.02, exceeding analysts' expectations.
• Overall, the stock currently holds a consensus rating of "Hold", with eight analysts recommending a Buy and others divided between Hold and Sell ratings.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Leerink Partnrs lifted their Q3 2026 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research note issued to investors on Monday, September 8th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $2.20 for the quarter, up from their previous forecast of $2.07. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share.

SRPT has been the subject of a number of other research reports. Cantor Fitzgerald reissued a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. The Goldman Sachs Group increased their price objective on Sarepta Therapeutics to $19.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Robert W. Baird increased their price objective on Sarepta Therapeutics from $30.00 to $35.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. TD Cowen downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price objective on the stock. in a report on Wednesday, June 18th. Finally, Barclays upgraded Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 price objective on the stock in a report on Tuesday, July 29th. Eight analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $39.32.

Sarepta Therapeutics Stock Up 1.2%

Shares of Sarepta Therapeutics stock traded up $0.21 during midday trading on Wednesday, hitting $17.60. The company's stock had a trading volume of 2,809,171 shares, compared to its average volume of 6,321,511. The firm has a market capitalization of $1.72 billion, a P/E ratio of -20.23 and a beta of 0.49. The stock has a 50-day simple moving average of $17.75 and a 200-day simple moving average of $40.39. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $138.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 EPS for the quarter, topping the consensus estimate of $0.89 by $1.13. The business had revenue of $611.09 million during the quarter, compared to analysts' expectations of $530.66 million. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.Sarepta Therapeutics's revenue was up 68.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in SRPT. New York State Teachers Retirement System increased its stake in shares of Sarepta Therapeutics by 3.3% in the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock worth $5,065,000 after purchasing an additional 2,512 shares during the period. Trexquant Investment LP bought a new position in shares of Sarepta Therapeutics in the first quarter worth about $11,997,000. Exchange Traded Concepts LLC bought a new position in shares of Sarepta Therapeutics in the first quarter worth about $479,000. GAMMA Investing LLC increased its stake in shares of Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock worth $2,607,000 after purchasing an additional 39,991 shares during the period. Finally, Scientech Research LLC bought a new position in shares of Sarepta Therapeutics in the first quarter worth about $968,000. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.